GMAB News and Press, Genmab A/S From 06/29/20

Seattle Genetics (NASDAQ: SGEN ) and collaboration partner Genmab A/S (NASDAQ: GMAB ) announce positive topline results from a Phase 2 clinical trial, innovaTV 204 , evaluating antibody-drug conjugate (ADC) tisotumab vedotin in patients with relapsed/refractory metastatic cervical cancer....

They say that good things come in threes. And that just might be true for AbbVie (NYSE: ABBV) . The big drugmaker started off the week by receiving good news on Monday. It then announced two positive developments on Wednesday, just in time for the company's top executives to participate in a...

By Máire Lane, PhD, CFA, Senior Research Analyst; Frank Jennings, PhD, Senior Portfolio Manager We look for breakthroughs in healthcare by examining what medical treatment could look like a decade more into the future. When we look for interesting investment ideas, we spend...

The pace of development for a handful of next-generation cancer therapies is about to get a huge boost. AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) signed a collaboration deal on Wednesday involving three clinical-stage cancer drug candidates, plus up to four additional candidates down...

AbbVie (NYSE: ABBV ) and Genmab A/S (NASDAQ: GMAB ) have signed a broad collaboration agreement to jointly develop and commercialize three of Genmab's bispecific antibodies and enter into a discovery research collaboration for future antibody therapeutics for cancer. More news on: AbbVie...

NORTH CHICAGO, Illinois and COPENHAGEN, Denmark , June 10, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that AbbVie and Genmab have signed a broad collaboration agreement to jointly develop and commercialize three of Genmab's early-stage in...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 05/13/2020. Please visit our Tracking Ole Andreas Halvorsen...

As expected, the European Commission approves  a subcutaneous fixed-dose formulation of Johnson & Johnson's ( JNJ -1.1% ) Darzalex (daratumumab) for the treatment of multiple myeloma. More news on: Johnson & Johnson, Genmab A/S, Healthcare stocks news, Read more ...

Genmab A/S (GNMSF) Q1 2020 Earnings Conference Call May 06, 2020, 12:00 ET Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - EVP & CFO Anthony Mancini - EVP & COO Conference Call Participants Trung Huynh - Crédit Suisse ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...